Surmodics this week announced it successfully used its Sublime radial access microcatheter in a patient for the first time.
The company designed the device to enable peripheral access for the delivery of diagnostic and therapeutic agents, such as drugs and stents, to treat various medical conditions.
Sublime is in limited market evaluation and with the full suite expected to launch in fiscal 2024, according to a news release. The portfolio will include 0.014 in., 0.018 in. And 0.035 in. high-performance peripheral microcatheters.
“For peripheral as well as coronary interventions, radial access is safer than femoral access and much preferred by patients,” said Dr. Ankur Lpdha, who completed one of the first procedures with the Sublime device at the Cardiovascular Institute of the South. “I’m pleased to report that the Sublime microcatheter performed exceptionally well during our first uses of the device in treating peripheral arterial disease.”
Dr. Pradeep Nair, an interventional cardiologist at the Cardiovascular Institute of the South, is also one of the first physicians to use the device.
Surmodics’ Sublime is available in five lengths ranging from 65-200 cm and is compatible with 0.014 in., 0.018 in. and 0.035 in. guidewires. The device uses Surmodics’ Pristyne hydrophilic coating for lubricity to improve traceability through vessel tortuosity. The dual stainless steel, locked-braid layers of the device work together to optimize torque control, push transmission and deliverability to distal target lesions.
The microcatheters are available in straight or angled tip configurations to access all types of peripheral vessels within their indicated size range.
“This successful first use of our Sublime microcatheters is a major milestone, not only for Surmodics, but for the countless patients who stand to benefit from peripheral arterial treatment,” said Gary Maharaj, president and CEO of Surmodics. “For years, torqueable microcatheters have enabled coronary operators to overcome the most extreme challenges presented by complex arterial disease. We are pleased to bring this industry-first capability to peripheral interventions.”
